普伐他汀对高胆固醇血症患者低密度脂蛋白脂肪酸谱的影响。

Effect of pravastatin on fatty acid profile of low density lipoprotein in patients with hypercholesterolemia.

作者信息

Hong C Y, Lin S J, Chang M S, Chiang B N, Shen P M, Shiao M S

机构信息

Department of Medicine, Taipei Veterans General Hospital, Taiwan, ROC.

出版信息

Prostaglandins Leukot Essent Fatty Acids. 1993 Feb;48(2):155-8. doi: 10.1016/0952-3278(93)90104-5.

DOI:10.1016/0952-3278(93)90104-5

PMID:8446653

Abstract

We gave pravastatin, an HMG-CoA reductase inhibitor, to 21 hypercholesterolemic patients for 12 weeks after they had been on dietary therapy for 12 weeks. In addition to inducing a significant reduction of total cholesterol and LDL-cholesterol, pravastatin significantly decreased the proportion of linoleic acid (18:2) and increased that of saturated (FA) (16:0 and 18:0) in the cholesterol ester of LDL. Linoleic acid was also reduced in the triglyceride of LDL. Besides, monounsaturated FA (16:1 and 18:1) were increased in the cholesterol ester, triglyceride and phospholipid of LDL, but the changes in monounsaturated FA were not statistically significant. The effect of pravastatin on the FA profile of LDL was similar to that of fibric acid derivatives. The mechanism as well as the clinical implication of these changes await further investigation.

摘要

我们对21名高胆固醇血症患者进行了为期12周的饮食治疗，之后给予他们HMG-CoA还原酶抑制剂普伐他汀，持续12周。除了显著降低总胆固醇和低密度脂蛋白胆固醇外，普伐他汀还显著降低了低密度脂蛋白胆固醇酯中亚油酸（18:2）的比例，并增加了饱和脂肪酸（FA）（16:0和18:0）的比例。低密度脂蛋白甘油三酯中的亚油酸也有所减少。此外，低密度脂蛋白胆固醇酯、甘油三酯和磷脂中的单不饱和脂肪酸（16:1和18:1）有所增加，但单不饱和脂肪酸的变化无统计学意义。普伐他汀对低密度脂蛋白脂肪酸谱的影响与纤维酸衍生物相似。这些变化的机制及其临床意义有待进一步研究。